The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

supported by Bain Capital investment Founded in 1678, Tanabe Pharma is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. Through the discovery and ...

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Bain Capital, a ...